CBU
NVCT icon

CIBC Bancorp USA’s Nuvectis Pharma NVCT Stock Holding History

CIBC Bancorp USA’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$918K Buy
944
+165
+21% +$1.85K ﹤0.01% 1124
2026
Q1 		$198K Buy
+779
New +$6.67K ﹤0.01% 1623

Other funds holding NVCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return

CIBC Bancorp USA's NVCT Position: Q2 2026 in Review

CIBC Bancorp USA increased its Nuvectis Pharma (NVCT) stake by 21% in Q2 2026, buying an estimated $1.85K and bringing the position to 944 shares worth $918K. The position accounts for ﹤0.01% of the portfolio, ranked #1124.

CIBC Bancorp USA first reported a position in NVCT in Q1 2026 and has held it in 2 quarters since. 75 funds tracked by Wall St. Rank hold NVCT as of Q2 2026.

  • CIBC Bancorp USA held 944 shares of Nuvectis Pharma worth $918K as of Q2 2026.
  • CIBC Bancorp USA bought 165 Nuvectis Pharma shares in Q2 2026, an estimated $1.85K.
  • Nuvectis Pharma made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q2 2026, its #1124 holding.
  • CIBC Bancorp USA first reported a position in Nuvectis Pharma in Q1 2026 and has held it in 2 quarters since.
  • 75 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2026.

Based on CIBC Bancorp USA's 13F filing for Q2 2026, filed 13 Aug 2026.